Lyft Donates $1 Million to ACLU After ‘#MuslimBan’
Lyft Donates $1 Million to ACLU After ‘#MuslimBan’ Protest
Ride-sharing company Lyft has announced that it would donate $1 million to the American Civil Liberties Union (ACLU) in the wake of weekend protests against President Donald Trump’s executive order restricting travel from several terror-prone countries.
In a letter to customers, Lyft’s co-founders, John Zimmer and Logan Green, wrote (original emphasis):
We created Lyft to be a model for the type of community we want our world to be: diverse, inclusive, and safe.
This weekend, Trump closed the country’s borders to refugees, immigrants, and even documented residents from around the world based on their country of origin. Banning people of a particular faith or creed, race or identity, sexuality or ethnicity, from entering the U.S. is antithetical to both Lyft’s and our nation’s core values. We stand firmly against these actions, and will not be silent on issues that threaten the values of our community.
We know this directly impacts many of our community members, their families, and friends. We stand with you, and are donating $1,000,000 over the next four years to the ACLU to defend our constitution. We ask that you continue to be there for each other – and together, continue proving the power of community.
Lyft’s co-owners provided no evidence that the executive order was based on banning people based on “faith” or any criteria other than national origin — something previous administrations, including President Barack Obama, have done for national security and other reasons.
Rival ride-sharing company Uber came under criticism after it dropped surge pricing for travelers at New York’s JFK airport during Saturday night’s protest. Though Uber apparently intended the gesture as a way to support the demonstration, it inadvertently broke a strike by local taxi drivers that had been organized to protest the executive order.
The ACLU has reportedly garnered more than $20 million in donations as a result of its leadership in filing lawsuits to stay the execution of Trump’s executive order, and its prominent role at the protests.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...
Continue Reading
Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....
Continue Reading
Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...
Continue Reading
Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...
Continue Reading
aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...
Continue Reading